Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
TEL AVIV, Israel, Nov. 07, 2017 -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Tuesday, November 14, 2017 at 8:30am Eastern Time to report third quarter ended September 30, 2017 financial results.
| Tuesday, November 14 @ 8:30am Eastern Time | |||||||
| Domestic: | 877-280-1254 | ||||||
| International: | 646-254-3366 | ||||||
| Conference ID: | 1013162 | ||||||
| Webcast: | https://edge.media-server.com/m6/p/avv5bjwq | ||||||
Replays, Available through November 28th:
Domestic: 888-203-1112
International: 719-457-0820
Replay Passcode: 1013162
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).
INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979
